Auris Medical Holding (EARS) Reports Q4 Loss of CHF0.16/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2015 Financial Results
March 14, 2016 6:35 AM EDTAM-101 Phase 3 pivotal trial (TACTT2) in acute inner ear tinnitus approaching completion of enrollment 2015 operating expenses of CHF 30.9 million at low end of previous full year guidance Conference call today at 8 a.m. Eastern Time / 1 p.m. Central European Time
ZUG, Switzerland, March 14, 2016 (GLOBE NEWSWIRE) --Â Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today provided a business update and announced financial results for the fourth quarter and full year ended December... More
